19 May 2023
bởiAudrey Abella
Revumenib, a novel potent, selective oral inhibitor of the menin-KMT2A interaction, demonstrated promising antileukaemic activity in children and adults with highly refractory acute leukaemia with KMT2Ar* or NPM1* mutation, a phase I dose-escalation study finds.